biosimilars

News

CEO of Novartis' generics unit quits, sparking sale speculat...

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.

Events

Pharma Forecasting Training with J+D Forecasting

Partner Content

Limited Places Available for J+D Forecasting Training Zurich

Limited places for J+D's Pharma Forecasting Training

News

Napp launches Neulasta biosimilar in UK

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following

News

EU steps closer to generics and biosimilars manufacturing wa...

A change to European rules on drug manufacturing that could benefit makers of generics and biosimilars is edging closer, after lawmakers agreed draft legislation that tweaks rules on export

News

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly in Europe – weakened cash cow product Humira.

Events